Statements (64)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:acquisition |
gptkb:Allergan's_Kythera_Biopharmaceuticals
gptkb:Immunomedics gptkb:Alder_BioPharmaceuticals gptkb:Neurocrine_Biosciences gptkb:Mavenclad gptkb:Allergan's_Natrelle gptkb:Allergan's_LifeCell gptkb:Celerion gptkb:Allergan's_Solstice_Neurosciences gptkb:Allergan's_SkinMedica Aimmune Therapeutics Allergan Kite Pharma Rinvoq Stemcentrx Allergan Aesthetics Allergan's Aesthetics portfolio Allergan's Botox Allergan's CoolSculpting Allergan's Juvederm Allergan's_Avanir_Pharmaceuticals Allergan's_Zymeworks |
gptkbp:awards |
Best Places to Work
Fortune 500 company DiversityInc Top 50 Human_Rights_Campaign_Corporate_Equality_Index_score_of_100 Top_Employer_in_the_U.S. |
gptkbp:CEO |
gptkb:Richard_A._Gonzalez
|
gptkbp:clinicalTrials |
Phase 3 trials for Rinvoq
Phase 3 trials for Skyrizi Phase 3 trials for Imbruvica Phase 3 trials for Venclexta over 100 clinical trials ongoing |
gptkbp:employees |
approximately 50,000
|
gptkbp:founded |
2013
|
gptkbp:founder |
gptkb:Richard_A._Gonzalez
|
gptkbp:headquarters |
gptkb:North_Chicago,_Illinois
|
https://www.w3.org/2000/01/rdf-schema#label |
AbbVie Inc.
|
gptkbp:industry |
pharmaceuticals
|
gptkbp:market |
approximately $200 billion (2022)
|
gptkbp:partnerships |
gptkb:Mayo_Clinic
gptkb:Duke_University gptkb:Harvard_University gptkb:University_of_California,_San_Francisco gptkb:University_of_Chicago |
gptkbp:patentCitation |
over 50,000 patents filed
|
gptkbp:philanthropy |
AbbVie_Foundation
|
gptkbp:products |
gptkb:Humira
|
gptkbp:research_focus |
oncology
neuroscience immunology virology |
gptkbp:revenue |
approximately $56 billion (2022)
|
gptkbp:stockExchange |
ABBV
|
gptkbp:subsidiary |
gptkb:AbbVie_S.r.l.
gptkb:AbbVie_Biotherapeutics AbbVie_Ltd. AbbVie_Deutschland_GmbH AbbVie_Japan,_Ltd. |
gptkbp:sustainability |
focus on community engagement
focus on environmental responsibility focus on diversity and inclusion focus on access to healthcare |